Addex Therapeutics Ltd
APE1
Company Profile
Business description
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Contact
Chemin des Mines 9
Geneva1202
CHET: +41 228841555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.20 | 39.70 | -0.44% |
| CAC 40 | 8,117.78 | 61.99 | -0.76% |
| DAX 40 | 25,440.81 | 127.75 | -0.50% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,697.57 | 47.13 | 0.44% |
| HKSE | 24,917.60 | 111.97 | 0.45% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 63,381.99 | 111.00 | -0.17% |
| NZX 50 Index | 13,568.57 | 7.88 | 0.06% |
| S&P 500 | 7,619.98 | 37.00 | -0.48% |
| S&P/ASX 200 | 8,706.70 | 43.20 | -0.49% |
| SSE Composite Index | 3,885.33 | 2.78 | -0.07% |